We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+63.05%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$494M
AUM Growth
+$147M
Cap. Flow
+$3.52M
Cap. Flow %
0.71%
Top 10 Hldgs %
82.27%
Holding
60
New
21
Increased
11
Reduced
10
Closed
15
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.6 years
Top 20 Avg Time Held
0.5 years

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$12M
2
AKTS icon
Aktis Oncology
AKTS
+$9.1M
3
VIR icon
Vir Biotechnology
VIR
+$7.57M
4
ELVN icon
Enliven Therapeutics
ELVN
+$7.19M
5
DXCM icon
DexCom
DXCM
+$6.27M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$10.4M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.35M
3
MCK icon
McKesson
MCK
+$7.81M
4
A icon
Agilent Technologies
A
+$5.65M
5
PFE icon
Pfizer
PFE
+$5.07M

Sector Composition

Rank Sector Weight
1 Healthcare 99.29%
2 Consumer Staples 0.54%
3 Consumer Discretionary 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DNTH icon
1
Dianthus Therapeutics
DNTH
$4.17B
$177M 35.76%
2,104,184
– –
2023 Q3
10 quarters
CGON icon
2
CG Oncology
CGON
$5.48B
$87.2M 17.67%
1,288,948
-183,751
-12% -$10.4M
2024 Q1
8 quarters
ORKA icon
3
Oruka Therapeutics
ORKA
$4.89B
$37.3M 7.55%
760,424
+100,000
+15% +$3.48M
2024 Q2
7 quarters
CATX icon
4
Perspective Therapeutics
CATX
$267M
$25.2M 5.11%
6,049,999
+2,839,266
+88% +$12M
2024 Q2
7 quarters
JBIO icon
5
Jade Biosciences
JBIO
$875M
$19.7M 3.99%
1,400,708
– –
2025 Q2
3 quarters
ELVN icon
6
Enliven Therapeutics
ELVN
$2.88B
$15.7M 3.18%
400,000
+259,700
+185% +$7.19M
2025 Q1
4 quarters
TEVA icon
7
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$13.6M 2.75%
450,100
+32,800
+8% +$1.06M
2025 Q1
4 quarters
CNTX icon
8
Context Therapeutics
CNTX
$22.1M
$13.1M 2.65%
4,998,267
-506,588
-9% -$1.18M
2024 Q2
7 quarters
RGEN icon
9
Repligen
RGEN
$11.7B
$9.17M 1.86%
77,800
+27,500
+55% +$3.84M
2025 Q2
3 quarters
PVLA icon
10
Palvella Therapeutics
PVLA
$1.83B
$8.73M 1.77%
70,000
+50,700
+263% +$5.29M
2025 Q4
1 quarter
MDT icon
11
Medtronic
MDT
$122B
$8.66M 1.75%
100,000
-7,600
-7% -$728K
2025 Q3
2 quarters
VIR icon
12
Vir Biotechnology
VIR
$1.77B
$8.51M 1.72%
+950,000
New +$7.57M
2026 Q1
0 quarters
AKTS icon
13
Aktis Oncology
AKTS
$890M
$8.38M 1.7%
+468,566
New +$9.1M
2026 Q1
0 quarters
IMUX icon
14
Immunic
IMUX
$96.9M
$7.44M 1.51%
669,941
+200,000
+43% +$1.79M
2024 Q1
8 quarters
DXCM icon
15
DexCom
DXCM
$33.1B
$5.65M 1.14%
+90,000
New +$6.27M
2026 Q1
0 quarters
EHC icon
16
Encompass Health
EHC
$12.6B
$4.06M 0.82%
42,000
+10,400
+33% +$1.07M
2025 Q2
3 quarters
BSX icon
17
Boston Scientific
BSX
$64B
$3.77M 0.76%
60,000
-54,500
-48% -$4.36M
2022 Q1
16 quarters
TENX icon
18
Tenax Therapeutics
TENX
$56.5M
$3.45M 0.7%
+215,934
New +$2.92M
2026 Q1
0 quarters
GILD icon
19
Gilead Sciences
GILD
$195B
$2.79M 0.56%
+20,000
New +$2.8M
2026 Q1
0 quarters
PHAT icon
20
Phathom Pharmaceuticals
PHAT
$607M
$2.77M 0.56%
249,390
+43,314
+21% +$547K
2021 Q4
17 quarters
KPTI icon
21
Karyopharm Therapeutics
KPTI
$7.96M
$2.58M 0.52%
463,741
+329,175
+245% +$2.51M
2022 Q4
13 quarters
CNC icon
22
Centene
CNC
$34.8B
$2.29M 0.46%
70,000
-49,400
-41% -$2.03M
2025 Q4
1 quarter
MSLE icon
23
Satellos Bioscience
MSLE
$145M
$2.18M 0.44%
+387,769
New +$3.81M
2026 Q1
0 quarters
SCYX icon
24
SCYNEXIS
SCYX
$38.9M
$1.91M 0.39%
260,208
– –
2023 Q2
11 quarters
NTRA icon
25
Natera
NTRA
$58.3B
$1.8M 0.36%
9,000
-2,800
-24% -$603K
2020 Q3
22 quarters
1
2 3

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q1 2026 Portfolio in Review

As of Q1 2026, Avidity Partners Management held 60 positions worth $494M, up 42% from $347M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Avidity Partners Management's Q1 2026 filing shows 21 new, 11 increased, 10 reduced and 15 closed positions. Its largest new stake was Aktis Oncology: 468,566 shares worth $8.38M. The largest sale was CG Oncology, an estimated $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Avidity Partners Management's largest Q1 2026 buy was Aktis Oncology: 468,566 shares worth $8.38M.
  • Avidity Partners Management added most to Perspective Therapeutics in Q1 2026, an estimated $12M increase.
  • Avidity Partners Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $10.4M.
  • Avidity Partners Management fully exited Alnylam Pharmaceuticals in Q1 2026, selling an estimated $8.35M.
  • Avidity Partners Management's ten largest holdings make up 82% of its $494M portfolio in Q1 2026.
  • Avidity Partners Management opened 21 new positions and closed 15 in Q1 2026.
  • Avidity Partners Management's portfolio value rose 42% quarter-over-quarter to $494M.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.